

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 24 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:23:01 ON 26 APR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:23:32 ON 26 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2007 HIGHEST RN 932710-95-7

DICTIONARY FILE UPDATES: 25 APR 2007 HIGHEST RN 932710-95-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10530571.str



chain nodes :

12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :
8-14 8-15 9-12 9-13 10-16 11-17 17-18 17-26 18-19 18-25 19-20 19-27
20-21 20-24 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11
exact bonds :
5-7 6-11 7-8 8-9 8-14 8-15 9-10 9-12 9-13 10-11 10-16 11-17 17-18
17-26 18-19 18-25 19-20 19-27 20-21 20-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-23
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 13:24:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 13:26:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 65 TO ITERATE

100.0% PROCESSED 65 ITERATIONS 26 ANSWERS
SEARCH TIME: 00.00.01

L3 26 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.90	174.11

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:26:37 ON 26 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2007 VOL 146 ISS 18
FILE LAST UPDATED: 25 Apr 2007 (20070425/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1328491 CAPLUS

DOCUMENT NUMBER: 146:190124

TITLE: Bioavailability enhancement of an active substance by supercritical antisolvent precipitation

AUTHOR(S): Majerik, Viktor; Charbit, Gerard; Badens, Elisabeth; Horvath, Geza; Szokonya, Laszlo; Bosc, Nathalie; Teillaud, Eric

CORPORATE SOURCE: Department of Chemical Engineering, Pannon University, Veszprem, H-8201, Hung.

SOURCE: Journal of Supercritical Fluids (2007), 40(1), 101-110
CODEN: JSFLEH; ISSN: 0896-8446

PUBLISHER: Elsevier B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

AB Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercrit. Antisolvent (SAS) process. Oxeglitazar was copptd. with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinylpyrrolidone (PVP K17) from six different solvents: Ethanol (EtOH), THF, dichloromethane (DCM), chloroform (CHCl₃), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixts.: EtOH/THF (50:50%, volume/volume) and EtOH/CHCl₃ (50:50%, volume/volume). Formulations were compared in terms of particle morphol., crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissoln. kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while expts. with PVP K17 resulted in quasi amorphous solid dispersions with high d. and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissoln. rate compared to raw drug and phys. mixts. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.

IT 280585-34-4, Oxeglitazar
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (bioavailability enhancement of an active substance by supercrit.
 antisolvent precipitation)
 RN 280585-34-4 CAPLUS
 CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-
 5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1253003 CAPLUS
 DOCUMENT NUMBER: 146:804
 TITLE: insulin sensitization for delaying puberty and
 increasing growth
 INVENTOR(S): De Zegher, Francis; Dunger, David; Ibanez, Lourdes
 PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.;
 Addenbrooke's Hospital
 SOURCE: PCT Int. Appl., 61pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125285	A1	20061130	WO 2006-BE60	20060523
WO 2006125285	B1	20070111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: GB 2005-10469 A 20050523
 OTHER SOURCE(S): MARPAT 146:804

AB In accordance with the purpose of the invention, as embodied and broadly
 described herein, the invention is broadly drawn to a new method of
 treatment, the use of agents to manufacture a composition of treatment or the
 composition
 of treatment for the prevention of rapidly progressive puberty, the
 prevention of early menarche or the modulation, more particularly the
 delay, of the tempo of puberty in a female mammal, preferably a human

girl, and the disorders related thereto. In a particular embodiment the present invention involves the use of at least one insulin-sensitizing agent such as metformin, any of the polymorphs of metformin or a pharmaceutically acceptable salt thereof for the preparation of a composition

of

treatment to modulate the tempo of pubertal progression in a girl. Metformin administration to girls experiencing precocious puberty resulted in normalization of pubertal progression to menarche, increased height gains, leaner body composition, and decreases indexes relating to insulin resistance.

IT 280585-34-4, Oxeglitazar


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(metformin-induced insulin sensitization for delaying puberty and increasing growth)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1345487 CAPLUS

DOCUMENT NUMBER: 144:69749

TITLE: Preparation of 3,3-dimethylbenzoxepin-5-ylalkenones as intermediates for antidiabetic pentadienoic acids

INVENTOR(S): Brunet, Michel; Le Borgne, Guy

PATENT ASSIGNEE(S): Merck Sante, Fr.

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1609786	A1	20051228	EP 2004-291616	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006002721	A1	20060112	WO 2005-EP5693	20050527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,				

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 EP 1758876 A1 20070307 EP 2005-747039 20050527
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV
 PRIORITY APPLN. INFO.: EP 2004-291616 A 20040625
 WO 2005-EP5693 W 20050527
 OTHER SOURCE(S): CASREACT 144:69749; MARPAT 144:69749
 GI




AB Title compds. [I; R = H, (substituted) alkyl, aryl; R1 = halo, cyano, NO2, CO2H, (halo)alkoxycarbonyl, etc.; p = 0-4], were prepared Thus, 3,3-dimethyl-7-ethyl-2,3,4,5-tetrahydrobenzoxazepin-5-one, triflic anhydride, and pyridine were refluxed together in CH2Cl2 for 4 h to give 100% 3,3-dimethyl-5-trifluoromethanesulfonyloxy-7-ethyl-2,3-dihydrobenzoxazepine. The latter was heated with Me vinyl ketone, (PPh3)2PdCl2, and Et3N in DMF at 70-75° for 5 h to give 96% (3E)-4-(3,3-dimethyl-7-ethyl-2,3-dihydrobenzoxepin-5-yl)buten-2-one.

IT 280585-64-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of dimethylbenzoxepinylalkenones as intermediates for antidiabetic pentadienoic acids)

RN 280585-64-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:523273 CAPLUS
 DOCUMENT NUMBER: 143:53517
 TITLE: Use of pentadienoic acid derivatives for the treatment of hyperuricemia
 INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeiller, Jean-Jacques; Brutzkus, Bertrand
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
EP 1686983	A1	20060809	EP 2004-797525	20041102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1886129	A	20061227	CN 2004-80035212	20041102
BR 2004017003	A	20070116	BR 2004-17003	20041102
PRIORITY APPLN. INFO.:			EP 2003-292973	A 20031128
			US 2003-527773P	P 20031209
			WO 2004-EP12381	W 20041102
OTHER SOURCE(S):		MARPAT 143:53517		
GI				



AB The use of a pentadienoic acid derivative of formula I (e.g., (2E,4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid) is claimed for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative
 IT 280585-34-4, (2E,4E)-5-(2,3-Dihydro-3,3-Dimethyl-7-methoxy-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-39-9, (2Z,4E)-5-(3,3-Dimethyl-7-methoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-

methylpenta-2,4-dienoic acid 280585-41-3, (2E,4E)-5-(3,3-Dimethyl-7,8-dimethoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-43-5, (2E,4E)-5-(3,3-Dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-45-7, (2E,4E)-5-(3,3-Dimethyl-2,3-dihydro-7-(para-chlorobenzoyl)-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-47-9, (2E,4E)-5-(3,3-Dimethyl-7-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-48-0, (2E,4E)-5-(3,3-Dimethyl-7,8-dichloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-50-4, (2E,4E)-5-(3,3-Dimethyl-7-bromo-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-51-5, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-8-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-53-7, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-55-9, (2E,4E)-5-(3,3-Dimethyl-7-trifluoromethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-57-1, (2E,4E)-5-(3,3-Dimethyl-7-phenyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280586-03-0, (2E,4E)-5-(3,3,7-Trimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 852550-63-1, (2E,4E)-5-(9-Methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of pentadienoic acid derivs. for treatment of hyperuricemia)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-43-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-45-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-47-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-48-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-50-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-51-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 280585-53-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-

yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-55-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-57-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-03-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852550-63-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:467780 CAPLUS

DOCUMENT NUMBER: 143:1300

TITLE: Use of pentadienoic acid derivatives for the prevention and/or the treatment of hyperuricemia
INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeller, Jean-Jacques; Brutzkus, Bertrand

PATENT ASSIGNEE(S): Merck Sante, Fr.

SOURCE: Eur. Pat. Appl., 45 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 339200	T	20061015	AT 2003-292973	20031128
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

EP 1686983 A1 20060809 EP 2004-797525 20041102
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1886129 A 20061227 CN 2004-80035212 20041102

BR 2004017003 A 20070116 BR 2004-17003 20041102

PRIORITY APPLN. INFO.:

EP 2003-292973 A 20031128

US 2003-527773P P 20031209

WO 2004-EP12381 W 20041102

OTHER SOURCE(S): MARPAT 143:1300

AB Use of pentadienoic acid derivs. for the prevention and/or the treatment
 of hyperuricemia and/or associated disorders or diseases. The use of a
 pentadienoic acid derivative of formula (I) for the preparation of a
 medicament for

the prevention or treatment of hyperuricemia and/or one or several associated
 disorders or diseases, and/or for reducing the serum uric acid level of a
 subject. Medical compns. for these prevention and/or treatment,
 comprising such a pentadienoic acid derivative

IT 280585-34-4 280585-39-9 280585-41-3
 280585-43-5 280585-45-7 280585-47-9
 280585-48-0 280585-50-4 280585-51-5
 280585-53-7 280585-55-9 280585-57-1
 280586-03-0 852550-63-1


RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)

(use of pentadienoic acid derivs. for prevention and the treatment of
 hyperuricemia)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-
 5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-
 5-yl)-3-methyl-, (2Z,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-43-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-45-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-47-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-48-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-50-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-51-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 280585-53-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-

yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-55-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-57-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-03-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852550-63-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:291092 CAPLUS

DOCUMENT NUMBER: 140:303553

TITLE: New metastable benzoxepine derivatives used for treating dyslipidemia, atherosclerosis, and diabetes, pharmaceutical compositions containing them, and their preparation processes by salt formation and acidulation

INVENTOR(S): Bosc, Nathalie; Festal, Didier; Boudet, Bernard

PATENT ASSIGNEE(S): Merck Sante, Fr.

SOURCE: Fr. Demande, 29 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845386	A1	20040409	FR 2002-12432	20021007
FR 2845386	B1	20060630		
CA 2502877	A1	20040415	CA 2003-2502877	20030901
WO 2004031166	A1	20040415	WO 2003-EP9680	20030901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003264139 A1 20040423 AU 2003-264139 20030901
 EP 1549630 A1 20050706 EP 2003-798880 20030901
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006503073 T 20060126 JP 2004-540566 20030901
 US 2006041007 A1 20060223 US 2005-530571 20050407
 PRIORITY APPLN. INFO.: FR 2002-12432 A 20021007
 WO 2003-EP9680 W 20030901
 OTHER SOURCE(S): MARPAT 140:303553
 GI




AB The invention is directed to the preparation of new metastable benzoxepines I by salt formation of I and precipitation of I by acidulation of the aqueous salt solution, and their use for treating dyslipidemia, atherosclerosis, and diabetes [n = 0, 1, or 2; R = independently alkyl, alkoxy, halo]. Thus, addition of aqueous NaOH solution to the stable form of I (R = OMe) (II), followed by acidulation with aqueous H2SO4 afforded the metastable form of II in 99% yield (m.p. = 151-153° by DTA). The metastable form has a higher sp. surface area than the stable form, while their densities are comparable.

IT 280585-34-4P
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate stable form, metastable product; preparation of metastable benzoxepines by salt formation and acidulation for treating dyslipidemia, atherosclerosis, and diabetes)

RN 280585-34-4 CAPLUS
 CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:457054 CAPLUS
 DOCUMENT NUMBER: 133:89445
 TITLE: Preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity
 INVENTOR(S): Brunet, Michel; Zeiller, Jean Jaques; Berthelon, Jean Jaques; Contard, Francis; Augert, Guy; Guerrier, Daniel
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039113	A1	20000706	WO 1999-EP10114	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2787789	A1	20000630	FR 1998-16574	19981229
FR 2787789	B1	20020614		
CA 2356680	A1	20000706	CA 1999-2356680	19991220
BR 9916633	A	20010925	BR 1999-16633	19991220
EP 1140893	A1	20011010	EP 1999-967960	19991220
EP 1140893	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 200104839	A2	20020429	HU 2001-4839	19991220
AU 759892	B2	20030501	AU 2000-24329	19991220
JP 2003517449	T	20030527	JP 2000-591024	19991220
RU 2228333	C2	20040510	RU 2001-120380	19991220
CN 1554651	A	20041215	CN 2004-10047645	19991220
NO 2001003242	A	20010628	NO 2001-3242	20010628
US 6596758	B1	20030722	US 2001-869518	20010629
ZA 2001006177	A	20021028	ZA 2001-6177	20010726
HK 1047584	A1	20050527	HK 2002-108653	20021129
PRIORITY APPLN. INFO.:			FR 1998-16574	A 19981229
			WO 1999-EP10114	W 19991220
OTHER SOURCE(S):		MARPAT 133:89445		
GI				



AB The title compds. I [X = O, S; A = (CH₂)sCO(CH₂)t, (CH₂)sCR₃R₄(CH₂)t and s = t = 0, or one of s and t is 0 and the other is 1; R₁, R₂ = H, alkyl, alkenyl, alkynyl, etc.; R = halo, cyano, NO₂, etc.] were prepared E.g., (2E,4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid was prepared The hypolipidemic and antidiabetic activity of I were

investigated.


IT 280585-34-4P 280585-39-9P 280585-41-3P
280585-43-5P 280585-45-7P 280585-47-9P
280585-48-0P 280585-50-4P 280585-51-5P
280585-53-7P 280585-55-9P 280585-57-1P
280585-60-6P 280585-64-0P 280585-66-2P
280585-68-4P 280585-70-8P 280585-72-0P
280585-74-2P 280585-77-5P 280585-81-1P
280585-83-3P 280585-93-5P 280586-01-8P
280586-03-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-43-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-45-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-47-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-48-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-50-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-51-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-53-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 280585-55-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-

benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-57-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-60-6 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-6-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-64-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-66-2 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-7-(4-methoxyphenyl)-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-68-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7,8-tetramethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-70-8 CAPLUS

CN 2,4-Pentadienoic acid, 5-[8-(4-fluorophenyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-72-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-8-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-74-2 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(1-methylethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-77-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethoxy)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-81-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-hydroxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-83-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-[4-(trifluoromethyl)phenyl]-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-93-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-cyclohexyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-01-8 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethoxy-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-03-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:23:01 ON 26 APR 2007)

FILE 'REGISTRY' ENTERED AT 13:23:32 ON 26 APR 2007

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 26 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:26:37 ON 26 APR 2007

L4 7 S L3 FULL

=> d his

(FILE 'HOME' ENTERED AT 13:23:01 ON 26 APR 2007)

FILE 'REGISTRY' ENTERED AT 13:23:32 ON 26 APR 2007

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 26 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:26:37 ON 26 APR 2007

L4 7 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.71

213.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.46

-5.46

STN INTERNATIONAL LOGOFF AT 13:30:06 ON 26 APR 2007